CapsoVision (NASDAQ:CV) Price Target Lowered to $10.00 at Benchmark

CapsoVision (NASDAQ:CV) had its target price decreased by Benchmark from $14.00 to $10.00 in a research note released on Friday morning,Benzinga reports. Benchmark currently has a speculative buy rating on the stock.

A number of other brokerages have also recently commented on CV. Wall Street Zen upgraded shares of CapsoVision to a “hold” rating in a research note on Saturday, January 10th. Weiss Ratings reaffirmed a “sell (e)” rating on shares of CapsoVision in a report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, CapsoVision has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

CapsoVision Stock Down 0.3%

Shares of CapsoVision stock opened at $7.51 on Friday. CapsoVision has a 12-month low of $3.43 and a 12-month high of $15.37. The stock has a market cap of $351.77 million and a P/E ratio of -3.43. The business’s 50 day moving average is $5.58 and its 200-day moving average is $6.25.

CapsoVision (NASDAQ:CV) last released its earnings results on Thursday, March 26th. The company reported $0.02 earnings per share for the quarter. The firm had revenue of $3.92 million during the quarter.

Institutional Investors Weigh In On CapsoVision

Several hedge funds have recently added to or reduced their stakes in CV. Deutsche Bank AG bought a new position in CapsoVision during the fourth quarter worth $47,000. Wells Fargo & Company MN raised its position in shares of CapsoVision by 66.4% in the fourth quarter. Wells Fargo & Company MN now owns 6,287 shares of the company’s stock valued at $67,000 after purchasing an additional 2,508 shares during the period. New York State Common Retirement Fund acquired a new stake in shares of CapsoVision during the 3rd quarter worth about $34,000. Virtu Financial LLC bought a new stake in shares of CapsoVision during the 4th quarter worth about $128,000. Finally, Millennium Management LLC bought a new stake in shares of CapsoVision during the 4th quarter worth about $163,000.

CapsoVision Company Profile

CapsoVision, Inc (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.